TABLE 3

Effects of l-NMMA on renal function and hemodynamic parameters (expressed as percentage change of each parameter)

Control subjectsWithout microalbuminuria
With microalbuminuria
NateglinideRosigliatzonePlacebo + oral antidiabetic drugRosiglitazone + oral antidiabetic drug
GFR3.8 ± 5.9−4.7 ± 5.42.1 ± 4.4−3.6 ± 3.4−2.3 ± 3.1
RPF−10.9 ± 2.5*−4.1 ± 3.4*−13.1 ± 4.3*−2.8 ± 6.6−9.6 ± 3.1*
Filtration fraction17.4 ± 4.2*−1.1 ± 2.5†16.5 ± 5.9*−0.8 ± 3.1†11.9 ± 3.8*
MAP9.9 ± 4.7*4.6 ± 1.8*7.6 ± 1.6*4.8 ± 1.9*6.5 ± 2.1*
Renal vascular resistance21.0 ± 4.3*16.5 ± 3.9*26.9 ± 5.7*14.7 ± 3.1*20.4 ± 3.2*
  • Data are means ± SE.

  • *

    * Indicates a significant change (P < 0.01) of the hemodynamic parameter after l-NMMA administration compared with the corresponding baseline parameter. P < 0.02 vs. rosiglitazone.